Please activate JavaScript!
Please install Adobe Flash Player, click here for download

Dental Tribune Middle East & Africa Edition

4Page 6 Media CME Intraoral impression-taking 4Page 10 Dental Cafe Signs of Depression 4Page 3 News ‘Healthy’ food gives you hay fever 2 Hours DENTAL TRIBUNE The World’s Dental Newspaper · Middle East & Africa Edition PUBLISHED IN DUBAI APRIL, 2012 NO. 3+4 VOL. 10 Johnson & Johnson has been hit with a $1.1 billion fine after an Arkansas judge found the drugmaker guilty of deceptively mar- keting the antipsychotic Risperdal in the US State. The ruling follows an earlier jury verdict that con- cluded the company and its Janssenunithadengagedin “false and deceptive acts” when it sent marketing let- ters to more than 6,000 Arkansas doctors in 2003 claiming Risperdal’s supe- rior safety compared with competing drugs. The state also argued false state- ments were made about the drug’s risks and side effects and that J&J marketed the drug for “unapproved uses, including various symp- toms in children and the elderly” despite authorities banning such ac- tions. According to Arkansas Attorney General Dustin McDaniel, the jury concluded that J&J had “lied to patients and doctors because they cared more about profits than people” and found the company had violated consumer- protection laws. This is the third lawsuit that has hit J&J’s back pocket regarding claims the drugmaker duped Medicaid programmes to overspend on the drug through misleading advertis- ing and downplaying the drug’s risks. A South Carolina case fined J&J $327 million, while the company was hit with a $258 million penalty in Louisiana. The company has appealed both these rulings. Meanwhile, a settlement in Texas saw the company pay out $158 million to resolve claims of illegal marketing. It isexpectedJ&Jwillalsoappeal the Arkansas ruling. A spokeswoman for J&J told Bloomberg: “It is our posi- tion that an individual state should not penalise a pharma- ceuticalcompanyforusingandFDA-approved package insert or decide for itself whether a company complies with FDA rules.” The State will also seek damages over the misleading statements in the letter as well as penalties for almost 20,000 sales calls, which were allegedly deceptive as well. Sales of Risperdal peaked in 2007 at $4.5 billion before losing patent protection, with the drug bring- ing in just $527 million in 2010. DT J&J slapped with $1.1bn fine for deceptive risperdal advertising PROMEDICA Dental Material GmbH phone: +49 43 21/5 41 73 · fax +49 43 21/5 19 08 · Internet: www.promedica.de · eMail: info@promedica.de high quality glass ionomer cements first class composites innovative compomers modern bonding systems materials for long-term prophylaxis temporary solutions bleaching products … All our products convince by excellent physical properties perfect aesthetical results Light-curing nano-ceram composite highly esthetic and biocompatible universal for all cavity classes comfortable handling, easy modellation also available as flowable version Dental desensitising varnish Glass ionomer filling cement perfectly packable consistency excellent durable aesthetics also available as application capsules Visit us at www.promedica.de 1 - Year Program in Implant Dentistry Oral Implantology A series of advanced seminars leading to the European title as “CERTIFIED ORAL IMPLANTOLOGIST” (European Association of Implantologists EDI and University of Cologne) Peter A. Ehrl Dr.med. Dr.med.dent. Dentist, Oral Surgeon, Specialist Implantology, Berlin, Germany Andrea Grandoch Dr. med. Ass. Prof. Anatomy University of Cologne, Germany Detlef Hildebrand Dr.med.dent. Dentist, Dental Technician, Specialist Implantology, Berlin, Germany Susanne Nahles Assistant Prof. at the Dept. of Oral and Maxillofacial Surgery, Charité, Berlin, Germany Uwe Sander Dr. med. Maxillofacial Surgeon, Berlin, Germany Istvan Urban DMD, MD Assistant Professor in Implant Dentisty Loma Linda University, School of Dentistry, USA Private Practice, Budapest, Hungary Dietmar Weng Dr.med.dent. Dentist, Dental Technician, Specialist iImplantology, Starnberg, Germany George Goumenos DDS, MS DrOdont, Periodontist, Athens, Greece Spyros Karatzas DDS, MS, DMD Periodontist, Patras, Greece General Dentist, Athens, Greece Stratis Papazoglou DDS, MS, PhD Assistant Professor University of Athens, Greece Assistant Professor of Prosthodontics, University of Athens, Greece Prosthodontist, Athens, Greece Lecturer, Dept. of Prosthodontics. University of Athens, Greece DrOdont, Maxillofacial Surgeon, Athens, Greece LIMITED NUMBER OF PARTICIPANTS For Registration & More Information: +30 210 21 32 084 Fax.: +30 210 22 22 785 middleeast@omnipress.gr website: www.omnipress.gr, www.omnicongresses.gr Media Partner: PERIOD 2012 Location: Athens - Berlin Tot : 16 days of clinical education. ñ Implantology from A - Z ñ Surgery to Prosthetics ñ Soft and Hard Tissue ñ Treatment of Complex Cases ñ Systems for Everyday's Office ñ 4 Live Surgeries ñ 8 Hands-on & Workshops ñ 40 ECTS (Credit points according to the European Credit Transfer System) Session I May 3 - 6, 2012 Session IV February 14 - 17, 2013 Berlin, Germany Program Chairman: Peter A. Ehrl Dr.med. Dr.med.dent. | Program Co-Chairman: Spyros Karatzas DDS, MS, DMD Program Fee 8.100€ 6th Group